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Abstract!
For this project, targeted imaging of pancreatic and ovarian cancers with inhibitor-derived probes 
was investigated. Fluorescent and radioactive derivatives of AZD2281, a poly(ADP-
ribose)polymerase-1 and -2 (PARP1/2) inhibitor, were screened in a panel of pancreatic and 
ovarian cancer cell lines found to overexpress PARP1/2. We hypothesized that the AZD2281-
derived probes would serve as accurate measures of PARP1/2 expression and inhibition. 
 
To test this hypothesis, a panel of pancreatic ductal adenocarcinoma and ovarian carcinoma cell 
lines were characterized by Western blot and immunocytochemistry for PARP1/2 expression. 
Cells were then treated with AZD2281-BODIPY FL, fixed, and stained with anti-PARP. 
Fluorescence at 515 nm (AZD2281-BODIPY FL) correlated with fluorescence at 670 nm (anti-
PARP), indicating that PARP1/2 expression level is associated with fluorescent signal strength 
of AZD2281-BODIPY FL in vitro.  
 
Four cell lines representing a range of PARP1/2 expression were xenografted into Nu/Nu mice 
and the tumors grown. Mice bearing four tumor types each were imaged with AZD2281-
BODIPY FL or 
18F-AZD2281, sacrificed, and their tumors excised for stand-alone imaging and 
Western blot. Tumor fluorescence at 515 nm and standardized uptake values (SUVs) from PET-
CT correlated with tumor PARP1/2 expression measured by Western blot, indicating that 
PARP1/2 expression level is a determinant of fluorescent and radioactive signal strength of 
AZD2281-based imaging agents in vivo. Significantly more AZD2281-BODIPY FL and 
18F-
AZD2281 accumulated in tumors than in control muscle, providing clear visualization of 
PARP1/2-overexpressing cells in vivo.  
 
Finally, 
18F-AZD2281 and 
18F-fluorodeoxyglucose (FDG), the currently favored imaging probe 
for PET-CT oncology studies, were compared in a cohort of mice bearing A2780 tumors in their 
flanks. Mice were subjected to PET-CT to obtain baseline SUVs for both 
18F-AZD2281 and 
18F-
FDG. Over the following three days, mice were given doses of unmodified AZD2281 drug and 
imaged with PET-CT in triplicate. While SUVs for 
18F-FDG were unchanged by administration 
of AZD2281, 
18F-AZD2281 SUVs were significantly reduced compared to baseline signal. 
These data indicate that PET-CT imaging with 
18F-AZD2281, but not 
18F-FDG, can quantify 
PARP1/2 inhibition in vivo. 
 
The most commonly performed PET study involves imaging cancers with the radiotracer 
fluorodeoxyglucose (
18F-FDG); however, glucose-avidity is not a cancer-specific trait and it 
varies between and within tumor types. Perhaps more importantly, changes in FDG uptake are 
not always predictive early markers of molecularly targeted cancer drugs, hence the need for 
other imaging agents. The overall goal of this study was to determine whether a newly 
developed, drug-derived small molecule imaging agent could be used to quantitate PARP 
inhibition in ovarian and pancreatic cancers. Measurement of PARP inhibition may improve 
clinical observation of progression and treatment efficacy in patients receiving PARP inhibitors. 
This research represents a step toward developing a more generic approach for the rapid 
codevelopment of companion imaging agents based on small-molecule therapeutic inhibitors. 
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Glossary!
 
!
18F   
18fluorine 
18F-FDG   fluorodeoxyglucose 
ADP   adenosine diphosphate 
BCA   bicinchoninic acid  
CT   computed tomography 
DMAC   dimethylacetamide 
DMSO   dimethyl sulfoxide 
DSB   double strand break 
IC50   half maximal inhibitory concentration 
FLT   
18F-fluorothymidine 
Gab   IgG antibody 
GAPDH   glyceraldehyde 3-phosphate dehydrogenase 
keV   kilo-electron volt 
Mab   IgM antibody 
PARP   poly(ADP-ribose) polymerase 
PBS   phosphate buffered saline 
PEG   polyethylene glycol 
PET   positron emission tomography 
PFA   paraformaldehyde 
RIPA   radioimmunoprecipitation assay buffer 
SSB   single strand break 
SUV   standardized uptake value 
TBS   tris-buffered saline 
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Chapter!1: Introduction!
1.1 Significance!!
Despite decades of intense research, cancers continue to be a threatening family of diseases. 
Cancers are often treated with inhibitors, which may or may not work for an individual patient 
based on the cancer’s particular genetic and metabolic properties. The complexity of managing 
ovarian and pancreatic cancers is a particularly demanding and challenging problem. The initial 
choice of chemotherapy regimen is important, as survival times are short and progression may 
preclude the patient from trying other agents. Functional imaging of biomarkers may allow for 
better understanding of cancers at the molecular level, permitting better management of these 
diseases.
1,2 
 
An estimated 22,240 women in the United States were diagnosed with ovarian cancer in 2013, 
and 14,030 women died of the disease.
3 Over sixty percent of ovarian cancers are diagnosed after 
metastasis has already occurred. While women with disease confined to regional lymph nodes 
have a 91.9% 5-year survival rate, women with metastatic disease have only a 27.3% survival 
rate at 5 years.
3 The poor survival rates may be partly explained by the high rates of recurrence, 
with 70% of stage III and IV patients and 20-25% of stage I and II patients relapsing after initial 
treatment.
4 While assays that stratify ovarian tumors into platinum chemotherapy “sensitive” and 
“resistant” categories have been developed, these assays do not predict the most effective 
regimen for a patient’s cancer.
5  
 
Pancreatic cancer struck an estimated 45,220 Americans and killed 38,460 in 2013.
6 They have 
an even more dismal prognosis than ovarian cancers: 5-year survival rates for patients with   6 
localized, regional spread, and metastatic disease are only 24.1%, 9.0%, and 2.0%, respectively.
6 
The overwhelming majority of patients are diagnosed after the cancer has spread regionally 
(27%) or has metastasized (53%).
6 Gene profiling is currently being studied to identify patients 
who are sensitive or resistant to the most common chemotherapeutic regimens,
7 though standard 
chemotherapy regimens in advanced pancreatic cancer have low response rates with 
improvement in survival times only on the order of months.
8 
 
Functional molecular imaging (such as positron emission tomography, or PET) for screening and 
diagnostic purposes is controversial, but it is already playing an important role in cancer staging 
and is increasingly being used to monitor disease progression, recurrence,
9 and treatment 
efficacy.
10,11 By far the most commonly performed PET study involves imaging cancers with the 
radiotracer fluorodeoxyglucose (
18F-FDG).
12 However, glucose-avidity is not a cancer-specific 
trait and it varies between and within tumor types.
13 For example, many benign adnexal 
conditions (including endometriosis, cystadenomas, teratomas, schwannomas, and even normal 
ovaries in menstruating women) may strongly take up 
18F-FDG, while borderline or mucinous 
ovarian adenocarcinomas may fail to take up more 
18F-FDG than background structures.
14 
Scanning for pancreatic cancers with 
18F-FDG can result in false negative results in patients with 
high serum glucose levels, and false positives can occur in patients with pancreatitis.
15 Indeed, 
PET imaging may miss tumors in any highly metabolically active
16 or inflamed
17 tissues.  
 
Employing radiotracers that bind specific molecular targets in cancer cells may present the 
opportunity to detect and monitor malignancy with improved specificity. Moreover, visualizing 
drug targets in vivo could predict which tumors are likely to respond to that drug in a 
chemotherapeutic regimen. This predictive ability might allow for rational, individualized   7 
treatment choice. Additionally, the increased specificity of targeted imaging may help clinicians 
to improve staging and monitoring of progression or development of resistance of ovarian and 
pancreatic cancers. For this project, I investigated a novel targeted radiotracer, discussed in 
section 1.4, for its potential utility in PET imaging pancreatic and ovarian cancers. This study 
represents one of the first attempts to measure targeted inhibition in cancers. 
1.2 Positron!Emission!TomographyXComputed!Tomography!
Positron Emission Tomography-Computed Tomography (PET-CT) has emerged as an important 
tool, especially in oncology, where it is widely used in cancer diagnosis and staging. PET-CT has 
been increasingly used to monitor cancer progression and treatment efficacy. Because this 
project investigated a novel targeted PET radiotracer, I will first aim to provide brief overviews 
of PET imaging and currently available radiotracers before discussing the need for an expanded 
group of imaging probes. 
1.2.1 Physics!of!PET!
PET imaging requires injection with radioactive tracers that decay by emission of positrons 
(positively charged particles with the mass of an electron). Positrons travel short distances, 
losing energy via scattering interactions with electron clouds of nearby atoms, before directly 
encountering an electron from an atom in the surrounding matter. The range, or distance 
traversed by the positron, depends on the energy of the positron (which, in turn, is a function of 
the radionuclide that emitted the positron). The joining of positron and electron results in mutual 
annihilation and the release of two 511 keV photons offset approximately 180° from each other.  
 
PET scanners contain opposing detectors that record the arrival of divergent annihilation photons 
if these photons arrive within a narrow time frame relative to one another. The photons are   8 
assumed to have originated at a collision point somewhere along the straight line between the 
two detectors that recorded the event. 
1.2.2 Combined!PETXCT!
PET by itself often produces unsatisfactory images. Because PET scanners detect annihilation 
points rather than positron emission points, there is a limit to the spatial resolution determined by 
the range of emitted positrons. (The most commonly used isotope, 
18fluorine or 
18F, produces low 
energy positrons that have a short range – maximum 2.4mm – that produce relatively high 
resolution images
18). Additionally, the residual momentum of the positron and subsequent non-
collinearity of the annihilation photons also limits the maximum spatial resolution achievable by 
PET alone: the assumption of collinearity by the image-processing algorithm typically mislays 
the coincidence line by less than 0.5°, with the effect of blurring by 1-2 mm depending on the 
diameter of the scanning ring.
19 Finally, attenuation limits the usefulness of standalone PET. 
Because photons traveling through the body may be absorbed or lose energy, fewer photons are 
detected than are emitted from deep regions while relatively more photons are detected from 
superficial structures, leading to information degradation and artifacts. 
 
The moderately low spatial resolution of PET and the lack of a well-defined anatomical 
reference frame in its images quickly led to the use of integrated PET-CT scanners, which 
perform PET and CT imaging in tandem during a single examination. CT scanners use x-rays to 
acquire high-resolution anatomical images and to perform attenuation correction. The 
combination of an anatomical and attenuation map from CT with the positron emission map from 
PET enables accurate assessment of the activity of deep body structures with appropriate 
damping of the signal from superficial structures. For this project, we used PET-CT for all 
experiments with 
18F-labeled radioactive imaging agents.   9 
1.2.3 Current!Radiopharmaceuticals!!
1.2.3.1 Fluorodeoxyglucose1
The isotope of choice in medical radiochemistry is 
18F. In addition to the relatively good spatial 
resolution afforded by the short range of its emitted positrons,
18 
18F has a relatively long and 
biocompatible half-life of 110 minutes, permitting the uncoupling of its synthesis and use (for 
example, allowing transport to distant sites that lack access to a cyclotron). Owing to its half-life, 
18F is suitable for imaging studies that may last several hours, but its half-life is short enough to 
keep radiation exposure to the injected patient within reasonable limits. 
 
Of all 
18F radiotracers devised, none is more widely used in medicine than 
18F-
fluorodeoxyglucose (
18F-FDG). Ninety-percent of all PET studies are performed for oncology 
patients using 
18F-FDG.
12 The rationale for use of a glucose analog in cancer imaging stems from 
the increased metabolic demands of malignant proliferating cells. Glucose-avid tumors import 
18F-FDG through overexpression of glucose transporters (e.g. GLUT1, GLUT3) and trap 
18F-
FDG in the cell via hexokinase-mediated phosphorylation. 
18F-FDG-6-phosphate cannot be 
assimilated into glycogen nor can it be further metabolized in glycolysis because it lacks a 
crucial 2’-hydroxyl group. Thus, tumor cells accumulate 
18F-FDG-6-phosphate to a greater extent 
than the surrounding normal tissue and can be visualized by PET. 
 
However, 
18F-FDG has its limitations (Table 1). Certain tissues in the body, such as brain, 
kidney, bladder, and myocardium, normally exhibit high levels of glucose uptake. Glucose-
avidity is thus not a cancer-specific trait, and it varies between and within tumor types.
13 
Moreover, 
18F-FDG PET imaging may miss tumors in metabolically highly active
16 or inflamed
17   10 
tissues. Changes in 
18F-FDG uptake are also not always predictive early markers of effects of 
molecularly targeted drugs. To reduce competition from unlabeled glucose and to minimize the 
effects of insulin on uptake of glucose (and its analogs) at normal tissues, use of 
18F-FDG also 
requires that the patient fasts and achieves blood glucose levels below 120-150 mg/dL
17,19, which 
may be problematic for diabetics.  
1.2.3.2 Other118Fluorine1Radiotracers1
In addition to 
18F-FDG, other 
18F radiotracers (many more than can be discussed here) have been 
developed for PET imaging. For example, fluoride ions can replace hydroxide ions in the bone’s 
inorganic hydroxyapatite matrix and 
18F-fluoride labels regions of altered bone metabolism, 
exploiting the amplified local blood flow, higher capillary permeability, and increased bone 
turnover that is characteristic of malignant bone lesions.
20 
18F-fluoride identifies the reactive bone 
process rather than tumor cells themselves, and is thus considered a nonspecific tracer for 
cancer.
18 
 
Other 
18F radiotracers have been developed that mark highly proliferative cells based on their 
increased rate of macromolecule synthesis. Some agents mark cells with elevated DNA synthesis 
rates, such as the nucleoside analogs 
18F-fluorothymidine (FLT), 
18F-fluorouridine, and 2’-
[
18F]fluoro-5-methyl-1-β-D-arabinofuranosyluracil (
18F-FMAU). These agents are taken up by 
rapidly dividing cells, trapped via phosphorylation, and persist due to inefficient degradation. In 
addition to nucleic acids, rapidly dividing tumor cells are known to generate large quantities of 
phospholipids like lecithin and subsequently take up large amounts of choline,
21 which led to the 
development of the probe 
18F-fluoroethylcholine. Probes that identify rapid cell proliferation 
have the advantage of being more tumor-specific than 
18F-FDG.
18  
   11 
Of the radiotracers that label rapidly dividing cells, 
18F-FLT has been most extensively studied. 
Although PET quantification of 
18F-FLT uptake has been shown to correlate with biopsy-based 
proliferation scores (such as the Ki-67 score in lung, brain, lymphoma, breast, colorectal, 
esophageal, and head and neck cancers, melanomas, and soft tissue sarcomas of the 
extremities),
22 the usefulness of 
18F-FLT versus 
18F-FDG remains controversial since 
18F-FLT is 
not incorporated into DNA
18 and therefore does not definitively reflect the rate of DNA 
synthesis.
16,18 
 
Besides proliferation, other common tumor features such as hypoxia and angiogenesis have also 
been explored in the development of novel PET radiotracers. 
18F-fluoromisonidazole (FMISO), 
derived from the antibiotic 2-nitroimidazole that targets anaerobes, is used to image tumor 
hypoxia (an important prognostic factor). Upon diffusion into cells, nitroimidazoles are reduced 
by a single electron to generate a radical anion species. In the absence of oxygen, the 
nitroimidazole radical fails to be reoxidized and covalently bonds to intracellular 
macromolecules and labels the hypoxic cell.
23 Clinical trials (summarized by Rice et al., 2011) 
investigating the angiogenesis marker 
18F-Galacto-RGD, which binds the capillary cell integrin 
αVβ3, have demonstrated the ability of the probe to measure integrin expression and angiogenesis 
in patients.
24 
1.2.3.3 Targeted1Imaging11
Much of the functional molecular imaging has focused on exploiting common cancer traits 
across tumor types, such as altered metabolism, proliferation, hypoxia, and angiogenesis. 
However, the appreciation of the patient-specificity of cancers makes the ability of molecular 
imaging to identify specific genotypes or phenotypes with targeted probes increasingly attractive. 
Some of the oldest targeted radiotracers, the 
18F-fluoroestradiols, can actually detect estrogen   12 
receptor positive breast tumors and may one day help non-invasively predict responsiveness to 
tamoxifen therapy.
25,26,18 Another example of targeted PET involves the radiotracer 
124I-cG250 
derived from a chimerized monoclonal antibody against carbonic anhydrase IX, an antigen 
expressed by 94% of renal clear-cell carcinomas.
27 Renal carcinomas are difficult to visualize 
with 
18F-FDG due to the high physiologic uptake of the probe by the normal kidney. 
124I-cG250 
permits cancer identification and stratification into aggressive (
124I-cG250 uptake-positive) and 
less aggressive (
124I-cG250 uptake-negative) phenotypes.
27 Other targeted PET radiotracers may 
similarly enable physicians to move beyond cancer detection towards increased sophistication in 
determining prognosis, selecting treatment, monitoring progression, and early identification of 
therapeutic resistance. 
1.3 PARP!in!Cancers!
For this project, we investigated the utility of a molecularly targeted probe against poly(ADP-
ribose)polymerase (PARP), an enzyme involved in both single strand break (SSB) and double 
strand break (DSB) repair, in imaging ovarian and pancreatic cancers. Some ovarian and 
pancreatic cancers (up to 82%
28 and 10%
29, respectively) have been shown to have inherited or 
sporadic BRCA mutations. BRCA1 and BRCA2 are proteins involved in homologous 
recombination repair mechanisms that mend DNA double strand breaks (DSBs).
30 BRCA-
deficient tumors rely on other DNA repair mechanisms such as those mediated by PARP to 
preserve genomic integrity.
31-33  
 
PARP1 and PARP2 are nuclear proteins that recognize sites of DNA damage and form large, 
branched chains of ADP-ribose on specific DNA-associated proteins, such as histones and 
themselves.
34-36 These poly(ADP-ribose) chains disrupt protein function and recruit potentially 
hundreds of proteins,
34 including XRCC1, which orchestrates base excision repair.
37 Tumors with   13 
defects in homologous recombination pathways, including BRCA1- and BRCA2-deficient 
cancers, have been shown to be sensitive to inhibition of PARP1-mediated DNA repair with 
PARP1 inhibitors alone or in combination with DNA damaging agents (e.g. cis-[Cl2Pt(NH3)2]).
31-
33,38 BRCA-deficient tumors
31-33 or tumors with non-BRCA defects in homologous 
recombination
38,39 are thought to be sensitive to PARP inhibitors due to the synthetic lethality 
originating from the elimination of both BRCA and PARP dependent DNA repair pathways.  
1.4 AZD2281Xbased!Imaging!Agents!
Several PARP inhibitors are currently in clinical trials for a variety of advanced cancers,
40,41 and 
the Weissleder group has developed fluorescent and radioactive imaging agents based on one 
such competitive inhibitor, AZD2281 (Olaparib; Figure 1A).
42,43,44 The Weissleder lab has shown 
that the radiofluorinated PARP1 inhibitor 
18F-AZD2281 synthesized by our group accumulates in 
a BRCA-mutant breast cell line that has high PARP1 expression (MDA-MB436), enabling the 
use of this inhibitor as a radiotracer for PET-CT of xenografts of this cell line in vivo.
44 Although 
we have imaged the increased PARP1 levels for BRCA-mutant breast cell lines (MDA-MB436) 
versus BRCA-wild type breast cancer cell lines (MDA-MD231), not much is known about 
PARP1 protein levels and activities in other tumor cells and in healthy cells.
34 Moreover, the 
ability of the 
18F-AZD2281 probe to accurately quantify varying levels of its PARP target had 
not been previously demonstrated. I investigated the relative levels of PARP1/2 in cancerous 
cells lines and healthy tissue to determine if the scope of AZD2281-derived imaging agents can 
be widened to different forms of cancer, specifically pancreatic ductal adenocarcinomas and 
ovarian cancers. We hypothesized that AZD2281-derived imaging agents would serve as an 
accurate measure of PARP1/2 expression.  
  !  14 
Chapter!2: Methods!
All experiments described in the following methods section were carried out by myself. HT1080 
H2b-apple cells were generated by Katherine S. Yang. 
18F-AZD2281 was synthesized by 
Edmund J. Keliher and Thomas Reiner. Experiments involving radiochemistry were performed 
in their presence.  
2.1 PARPX1!IC50!Determination!
PARP-1 activity in the presence of graduated amounts of AZD2281-BODIPY FL was measured 
in vitro with a commercially available colorimetric assay (Trevigen, Gaithersburg, MD). 
Triplicate experiments with varying concentrations of AZD2281-BODIPY FL (3.3 μM to 0.1 
nM) were performed using 0.5 units PARP high-specific activity (HSA) enzyme in histone-
coated 96-well plates, each incubated for 10 minutes. Positive control wells contained no 
AZD2281-BODIPY FL. Negative control wells had no PARP-1. Each well contained a final 
volume of 50 μL with a final concentration of 2% DMSO in assay buffer. The rest of the assay 
was carried out according to the manufacturer’s instructions. A Tecan Safire
2 microplate reader 
(Tecan Group, Mannedorf, Switzerland) was used to measure PARP-1 activity via absorbance at 
450 nm. Calculation of IC50 values was performed using Prism software (GraphPad, La Jolla, 
CA).  
2.2 PARPX2!IC50!Determination!
PARP-2 activity in the presence of graduated amounts of AZD2281-BODIPY FL was measured 
in vitro with a commercially available chemiluminescence assay (BPS Biosciences, San Diego, 
CA). Triplicate experiments with varying concentrations of AZD2281-BODIPY FL (3.3 μM to 
0.1 nM) were performed using 50 ng PARP-2 enzyme in histone-coated 96-well plates. Positive 
control wells contained no AZD2281-BODIPY FL. Negative control wells had no PARP-2. Each   15 
well contained a final volume of 50 μL with a maximum final concentration of 2% DMSO in 
assay buffer. The rest of the assay was carried out according to the manufacturer’s instructions. 
A Tecan Safire
2 microplate reader (Tecan Group, Mannedorf, Switzerland) was used to measure 
PARP-2 activity via chemiluminescence. Calculation of IC50 values was performed using Prism 
software (GraphPad, La Jolla, CA).  
2.3 Cell!Culture!!
Cell lines were obtained from Prof. Michael Birrer’s lab at Massachusetts General Hospital (UCI 
101, UCI 107, OVCAR429, A2780), Katy Yang in the Weissleder lab (HT1080 stably 
expressing H2b-apple), and the ATCC (all remaining cell lines). Cells were cultured in their 
respective appropriate growth media. Briefly, MDA-MB231, MDA-MB436, MIA PaCa2, 
A2780, OVCAR429, UCI 101, and UCI 107 cells were grown in RPMI 1640 with 10% fetal 
bovine serum, L-glutamine, and penicillin/streptomycin. RAW 264.7, PANC1, CaOV3, and 
HT1080 cells were grown in DMEM with 10% fetal bovine serum, 2% sodium bicarbonate, L-
glutamine, and penicillin/streptomycin. SKOV-3 cells were grown in McCoy’s 5A medium with 
10% fetal bovine serum, L-glutamine, and penicillin/streptomycin. OVCAR-3 cells were grown 
in RPMI 1640 with 20% fetal bovine serum, 1% bovine insulin, L-glutamine, and 
penicillin/streptomycin. OV-90 cells were grown in 50% MCDB 105 medium, 50% Medium 199 
with 15% fetal bovine serum, and 2% sodium bicarbonate. All cell lines were incubated at 37°C 
and 5% CO2. Cells were harvested by trypsinization (0.25% trypsin-EDTA) for all experiments 
involving cells. 
2.3.1 HT1080!H2bXapple!!
Katy Yang transformed the HT1080 cell line to stably express H2b-apple as detailed in Reiner et 
al 2012.
45    16 
2.4 In1vitro1Imaging!of!AZD2281XBODIPY!FL!
Unless otherwise noted, all in vitro images were captured on the Deltavision (Applied Precision 
Instruments) and Olympus IX71 microscopy system and fluorescence intensities were calculated 
using public domain ImageJ software (National Institutes of Health, Bethesda, MD).  
2.4.1 Cell!imaging!
To determine if probe uptake occurs specifically at the molecular targets of AZD2281 (i.e. 
PARP1/2), AZD2281-BODIPY FL in vitro imaging and blocking experiments were performed. 
MIA PaCa2, MDA-MB231, and MDA-MB436 cells (200 μL, 50,000 cells/mL) were seeded into 
glycerine-treated 8-well chamber slides (Lab Tek
TM, Thermo Scientific, Rochester, NY), and 
allowed to attach over night. Cells were then incubated with AZD2281 (2 μL, 1 mM) or medium 
(1% DMSO) for 20 minutes (37 °C) before the medium was removed and cells were washed (1x, 
medium, 500 μL). Subsequently, 200 μL medium and AZD2281-BODIPY FL (2 μL, 100 μM) 
were added and incubated at 37 °C for 15 min. Cells were washed with PBS (1x 500 μL), fixed 
with paraformaldehyde (4% in PBS) and washed with PBS/0.1% Triton X-100/0.5% bovine 
serum albumin (3x 500 μL, 3rd wash left for 15 min), before they were incubated with anti-
PARP-1 Mab (1:200; Millipore, Billerica, MA) at 4 °C over night. Cells were washed with 
PBS/0.1% Triton X-100 (3x 200 μL) before they were stained with secondary IgG-Cy5 Gab 
(1:100; Millipore, Billerica, MA) for 3h at 4 °C. Cells were then washed with PBS (1x, 200 μL), 
stained with Hoechst (Invitrogen, Carlsbad, CA) and blue whole cell stain (Thermo Scientific, 
Rochester, NY) for 30 min at room temperature, and washed with PBS (3x, 200 μL) before 
imaging on the Nikon 80i (60x, 1x zoom). 
2.4.2 CoXlocalization!of!AZD2281XBODIPY!FL!and!PARP1/2!
To characterize the AZD2281-BODIPY FL co-localization with PARP1/2 in cells, RAW 264.7, 
PANC1, MIA PaCa2, A2780, OVCAR429, UCI 101, UCI 107, SKOV-3, OVCAR-3, and OV-90   17 
cells (200 μL of 35,000 cells/mL) were plated in their appropriate growth media on 96-well 
plates then allowed to attach for 48 hours. The cells were then incubated with AZD2281-
BODIPY FL (2 μL, 100 μM, 20 min, 37 °C). The medium was removed and cells were washed 
(1x, medium, 200 μL and 2x 1X PBS), fixed (4% PFA in PBS) and permeabilized (ice cold 
PBS/0.1% Triton X-100/0.5% bovine serum albumin for 3x 200 μL permeabilizations: 2x 5 min 
and then 1x 30 min). Next, anti-PARP1/2 polyclonal antibody (1:50; Santa Cruz Biotechnology, 
Santa Cruz, CA) was applied and incubated at 4 °C over night. Then, the cells were washed with 
PBS/0.1% Triton X-100 (3x 200 μL) and stained with secondary IgG-Cy5 goat antibody (1:100; 
Millipore, Billerica, MA) for 3h at 4 °C. Cells were washed with PBS (1x, 200 μL), stained with 
Hoechst 33342 (Invitrogen, Carlsbad, CA) and blue whole cell stain (Thermo Scientific, 
Rochester, NY) for 30 min at room temperature, and washed with PBS (3x, 200 μL) before 
imaging. Imaging was done on a DeltaVision microscope (Applied Precision Instruments) at 
20X, with 1.6 zoom. For each cell line, 9 distinct regions were measured per well. All cell lines 
were measured in biological and technical triplicate. AZD2281-BODIPY FL fluorescence was 
measured and calculated by quantification of fluorescence signal and subtraction of green 
autofluorescence in the respective cell lines. PARP1/2 expression levels were measured and 
calculated by quantification of the fluorescence signal and subtraction of nonspecific secondary 
IgG-Cy5 Gab staining. Using open source image processing package Fiji for ImageJ, co-
localization of anti-PARP1/2 and AZD2281-BODIPY FL fluorescence signals was quantified as 
a Pearson’s correlation coefficient comparing intensity of each pixel in the red and green 
channels, respectively (Rcoloc = 0.95).  
2.4.3 Western!Blot!!
Western blots were performed to determine PARP1/2 expression for both cultured cell line 
samples as well as excised tumors from sacrificed mice (see section 2.5.6). Samples were   18 
suspended in 1x RIPA buffer and 2x Mini Complete Protease Inhibitor Cocktail tablet (Roche, 
Indianapolis, IN). The samples were centrifuged at 4°C, 10,000 rpm for 10 minutes and the 
protein-containing supernatant saved. The protein concentration of each sample was measured 
with a BCA Protein Assay performed according to manufacturer’s instructions (Therno 
Scientific, Rochester, NY). 10 μg of the supernatant was loaded on NuPAGE Novex 4-12% Bis-
Tris 1.0 mm gels and subjected to electrophoresis (XCell SureLock Mini-Electrophoresis system; 
Invitrogen, Carlsbad, CA). Protein was transferred to a nitrocellulose membrane (iBlot Dry 
Blotting System; Invitrogen, Carlsbad, CA). Blocking the blot was achieved in 5% skim milk for 
1 hour. The blot was then washed with 1x TBS-Tween 20 (Boston BioProducts, Ashland, MA) 
and incubated overnight at 4°C with 1:1000 anti-PARP1/2 in 5% skim milk (Santa Cruz 
Biotechnology, Santa Cruz, CA). Following three 5-minute washes and three 30-minute washes 
with 1x TBS-Tween 20, the blots were incubated with 1:5000 goat anti-rabbit secondary 
antibody at room temperature for 1hour. Then, three 5-minute washes with 1x TBS-Tween 20 
were performed and blots were incubated with SuperSignal West Pico Chemiluminescent 
Substrate (Thermo Scientific, Rochester, NY), exposed for 20 minutes (PARP), and processed 
with the Kodak X-OMAT 2000A processor.  
 
For GAPDH blots (after blocking and following three 5-minute washes with 1x TBS-Tween 20), 
blots were incubated for one hour at room temperature with 1:5000 anti-GAPDH in 5% skim 
milk (R&D Systems, Minneapolis, MN). Following three 5-minute washes with 1x TBS-Tween 
20, blots were incubated with donkey anti-goat secondary antibody at room temperature for 1 
hour. Following three 5-minute washes with 1x TBS-Tween 20, blots were incubated with 
SuperSignal West Pico Chemiluminescent Substrate for 5 minutes (Thermo Scientific, 
Rochester, NY), exposed for 10 seconds, and processed with the Kodak X-OMAT 2000A   19 
processor.  
2.5 In1vivo1Imaging!of!AZD2281XBODIPY!FL!and!18FXAZD2281!
C57BL/6J (B6) mice were obtained from the Jackson Laboratory. Nu/Nu mice (Cox-7) were 
obtained from Massachusetts General Hospital, Boston, MA. For all surgical procedures and 
imaging experiments, mice were sedated by 2.0 L/min isoflurane:2.0 L/min oxygen. For imaging 
experiments of more than 1 hour, the isoflurane was slowly reduced to 0.8 to 1.2 L/min. 
Surgeries were conducted by Rostic Gorbatov under sterile conditions with a zoom 
stereomicroscope (Olympus SZ61). Approval from the subcommittee on Research Animal Care 
at Massachusetts General Hospital was obtained for all animal protocols. 
2.5.1 Tumor!Xenografts!
To determine in vivo 
18F-AZD2281 uptake, Nu/Nu mice each received four subcutaneous 
injections containing either SKOV-3, MIA PaCa2, A2780, or PANC1 cells in the flanks and 
shoulders (2.5x10
6 cells in 100 μL 70:30 PBS/BD matrigel per injection) (BD Biosciences, 
Bedford, MA). I grew all cell lines and prepared all cancerous cells for tumor injections. Either 
Rostic Gorbatov or I implanted tumors in all mice. Tumors were allowed to grow for two weeks 
before imaging. 
 
For dose-response experiments, Nu/Nu mice each received two subcutaneous injections 
containing A2780 cells in the flanks (4x10
6 cells in 100 μL 70:30 PBS/BD matrigel per injection) 
(BD Biosciences, Bedford, MA). I grew all cell lines and prepared all cancerous cells for tumor 
injections. Either Greg Thurber or I performed tumor injections in all mice. Tumors were 
allowed to grow for two weeks before imaging.   20 
2.5.2 Window!Chambers!
To determine if AZD2281-BODIPY FL accumulated in normal cells (e.g. macrophages) or 
tumor cells in vivo, HT1080 expressing H2b-apple (1x10
6 cells, 50 μL 1X PBS) were implanted 
into Dorsal Skin Chambers (DSCs, APJ Trading Co, Inc.) into the dorsal skinfold of Nu/Nu mice 
as described previously 
46-49. DSCs were surgically placed by Rostic Gorbatov, while implanted 
cells were prepared by me. To allow neovascularization, HT1080 tumors were allowed to grow 
for 8 days. On one side, the skin was surgically removed by Rostic Gorbatov and replaced by a 
10 mm diameter optical glass cover slip held in place with a c-clip. Spacers between the both 
halves of the DSC frame prevent excessive compression of the tissue and vessels.  
 
I injected mice bearing HT1080 tumors in their DSCs with 75 nmoles of AZD2281-BODIPY FL 
(7.5 µL DMSO, 67.5 µL, DMAC:Solutol (1:1), 150 µL 1X PBS). Immediately after injection, 
the accumulation and distribution of AZD2281-BODIPY FL in tumor tissue was monitored with 
the help of Rainer Kohler using the customized Olympus FV1000MPE based on a BX61-WI 
confocal microscope. Data was collected with an Olympus XLUMPLFLN 20x water immersion 
objective (numerical aperture/NA 1.0) and a LUMFLN (NA 1.10) water immersion objective. 
Excitation of AZD2281-BODIPY FL and H2b-apple was performed sequentially using a 473-nm 
and 599-nm diode laser, respectively, in conjunction with a DM405/488/559/635-nm dichroic 
beam splitter. Separation and collection of emitted light was performed with the SDM560 beam 
splitter and BA490-540 and BA575-675 band pass filters. Photobleaching and phototoxicity 
were avoided through protocol optimization using control tumors. Similar setups of lasers, 
splitters, and filters were used for all in vivo fluorescent imaging.   21 
2.5.3 Fluorescence!Imaging!
Nu/Nu  mice  bearing  A2780,  PANC1,  MIA  PaCa2  and  SKOV-3  tumors  in  their  flanks  and 
shoulders (n=2) were injected with either AZD2281-BODIPY FL (75 nmoles in 7.5 µL DMSO, 
67.5 µL PEG400, 150 µL 1X PBS) or vehicle prepared by me and sacrificed 45 minutes post-
injection. Tumors and muscle tissue from both experimental and control cohorts were excised by 
Thomas Reiner and Ned Keliher, and tissue fluorescence values were measured simultaneously 
on the Olympus OV110. Probe uptake for each tissue sample was calculated as 
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Equation 1. AZD2281-BODIPY FL uptake was calculated with measurements obtained on the Olympus OV110. 
2.5.4 Radioactive!Imaging:!PETXCT!
PET-CT images were acquired as reported previously in Hendricks et al., 2011.
50 All PET-CT 
was performed with the assistance of Jessica Truelove using a Siemens Inveon PET-CT. PET 
signal was calibrated before every scan by scanning an 8.0 cm phantom holding a known amount 
of 
18F isotope. Each PET acquisition lasted 45 minutes; 450 million coincidental 511 keV photon 
counts were registered by lutetium oxyorthosilicate crystal rings per acquisition. Photon counts 
were rebinned by only registering photons that bridged three or fewer consecutive rings and by 
applying a high resolution Fourier Rebin algorithm to reconstruct sinograms. The sinograms 
were then transformed into a three dimensional map of positron emission using a 2D filtered 
back-projection algorithm with Ramp filter at Nyquist cutoff of 0.5. Dimensions of image pixels 
were 0.861 mm in the x and y directions, and 0.796 mm in the z direction (total 128x128x159 
pixels). 
 
Using the Hounsfield unit scale, CT calibration was performed before acquisition with an 8.0 cm   22 
cylindrical phantom holding water. 360 X-ray projections (cone beam angle = 9.3˚) over the 360˚ 
perpendicular to the animal bed were used for CT reconstruction. A 500 A anode source placed 
346 mm from the center of rotation sent 80 kV X-rays to the animal bed. Projections were 
recorded on a CCD detector containing 2048 transaxial and 3072 axial pixels, calibrated with 70 
dark and 70 light images, interpolated bilinearly, processed through a Shepp Logan filter, and 
reconstructed with a filtered back projection algorithm. Final isotropic CT pixel size was 110.6 
m and a total of 512x512x768 pixels were recorded. 
2.5.5 AZD2281XBODIPY!FL!and!18FXAZD2281!Blood!HalfXlives!and!
Biodistribution!
Thomas Reiner, Rainer Kohler, and I determined AZD2281-BODIPY FL blood half-life. Nu/Nu mice 
were implanted with dorsal skin chambers and injected with HT1080 cells as described in section 2.5.2. 
One mouse was injected with 2 nmol of AZD2281-BODIPY FL formulated in 60:40 PEG400/PBS by 
tail vein catheter. Light emission for three regions of interest in both vasculature and extravascular 
stroma was measured with the Olympus IV110. Data were recorded every ten seconds for one minute 
before and nine minutes after probe injection, followed by recordings every two minutes for ten 
minutes, and finally by recordings every 5 minutes up through 45 minutes post-injection. A final data 
point at 64 minutes post-injection was also recorded.  
18F-AZD2281 blood half-life was determined by Thomas Reiner and Ned Keliher with three C57BL/6 
mice administered with 34 ± 5 µCi 
18F-AZD2281 by tail vein intravenous injection formulated in 5% 
DMSO in 1X PBS (75 µL). Blood sampling was performed by retro-orbital bleed using heparinized 
capillary tubes. Samples were weighed, and activity was measured by Perkin Elmer Wallac Wizard 3” 
1480 Automatic Gamma counter.  
Blood-half life data were fit to biexponential models in GraphPad Prism 4.0c (GraphPad Software Inc., 
San Diego, CA) and are calculated as the weighted averages of the distribution and clearance phases.    23 
For biodistribution studies, six C57BL/6 mice were injected with 43 ± 5 µCi or 410 ± 22 µCi 
18F-
AZD2281 in 5% DMSO in 1X PBS (75 µL) by tail vein intravenous injection by Thomas Reiner and 
Ned Keliher. Animals were sacrificed at 2 h (n = 3) or 18 h (n = 3) after injection. Tissues were excised 
and weighed, and activity was measured by Perkin Elmer Wallac Wizard 3” 1480 Automatic Gamma 
counter. GraphPad Prism 4.0c was used for statistical analysis. 
2.5.6 18FXAZD2281!Imaging!
All work involving handling of radioactivity was undertaken with the help of Thomas Reiner and 
Ned Keliher, who are both on the Weissleder lab’s radioactivity research permit. To perform in 
vivo imaging of PARP1/2 expression, Nu/Nu mice bearing A2780, PANC1, MIA PaCa2 and 
SKOV-3 tumors (n = 3) in their left and right flanks and left and right shoulders, respectively, 
were injected with 500 ± 50 µCi 
18F-AZD2281. Ninety minutes post-injection, the mice were 
subjected to PET imaging. Standardized uptake values (SUVs) determined by PET imaging are 
defined as 
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Equation 2. Definition of standardized uptake value (SUV). 
and were calculated following PET and CT image fusion by drawing tumor SUV margins to 
contain the entire tumor (guided by the aid of the CT image) using the Siemens Research 
Workplace v3.0 analysis application. 
 
Mice were then sacrificed, and their tumors were excised and snap frozen in liquid nitrogen. 
Following decay of the radioactive tracer, I homogenized tumors in 400 μL 1x RIPA buffer and 
2x Mini Complete Protease Inhibitor Cocktail tablet (Roche, Indianapolis, IN). I then performed 
Western blots to probe for PARP1/2 expression in the excised tumors as described above.    24 
 
In order to compare PET images acquired with 
18F-FDG vs. 
18F-AZD2281 in the absence and 
presence of AZD2281, Nu/Nu mice bearing A2780 tumors (n = 3) in their flanks were injected 
with 440 ± 40 µCi 
18F-AZD2281 via tail vein by Thomas Reiner or Ned Keliher. Two hours 
post-injection, the mice were subjected to the first round of PET imaging. Thereafter, the same 
mice were reinjected with 523 ± 47 µCi 
18F-FDG and subjected to a second round of PET 
imaging. After 
18F-FDG imaging, the mice were injected with 1 mg AZD2281 formulated in 
1:1:4 DMAC:Solutol: PBS (100 µL) intraperitoneally. The next day, mice were treated with 0.5 
mg AZD2281 in 1:1:4 DMAC:Solutol:PBS (50 µL) intravenously. Mice were then imaged as 
they were on the first day. Three replicates of this treatment/imaging cycle were performed on 
the same mice over the following three days. A total of ten complete serial sessions were 
obtained for each mouse. At the conclusion of the experiment, mice were sacrificed, and their 
tumors were excised and activity was measured by Perkin Elmer Wallac Wizard 3” 1480 
Automatic Gamma counter. SUVs were calculated following PET and CT image fusion by 
drawing tumor SUV margins to contain the entire tumor (guided by the aid of the CT image) 
using the Siemens Research Workplace v3.0 analysis application. SUV data from 
18F-AZD2281 
PET images were decay-corrected to the start of 
18F-FDG PET imaging and used to correct 
18F-
FDG SUV data. 
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Chapter!3: Results!
3.1 In1vitro!behavior!of!AZD2281Xderived!imaging!agents!
3.1.1 Chemical!data!
Chemical structures for AZD2281, AZD2281-BODIPY FL, and 
18F-AZD2281 are provided in 
Figure 1. Half-maximal inhibitory concentrations (IC50) of AZD2281 against PARP1 and PARP2 
have been reported elsewhere as 5 nM and 1 nM, respectively.
51 Using commercially available 
PARP1 and PARP2 inhibition assays and statistical analysis software GraphPad Prism as 
described in sections 2.1 and 2.2, I determined that the IC50 values for AZD2281-BODIPY FL 
against PARP1 and PARP2 were 12.2 ± 1.1nM and 1.92 ± 1.2 nM, respectively (Figure 2). I also 
determined that the IC50 value for 
19F-AZD2281 against PARP1 is 17.9 ± 1.1 nM (Figure 3). 
3.1.2 PARP1/2!expression!data!
In order to obtain a qualitative estimate of relative PARP1/2 expression levels across cell lines, I 
performed Western blots with protein lysate collected from harvested cell lines as described in 
section 2.4.3. All cancerous cell lines exhibited increased PARP1/2 expression compared to 
benign control cell line Hs832 (Figure 4). 
3.1.3 Competitive!inhibition!using!AZD2281!
To determine if probe uptake occurs specifically at the molecular targets of AZD2281 (i.e. 
PARP1/2), I performed AZD2281-BODIPY FL in vitro imaging and blocking experiments as 
outlined in section 2.4.1. If AZD2281-BODIPY FL binds to PARP1/2, addition of excess 
AZD2281 to cells should displace (or “block”) AZD2281-BODIPY FL from the enzymes’ active 
sites and result in lower nuclear fluorescence intensity. Indeed, lower fluorescence at 515nm was 
observed in cells treated with both AZD2281-BODIPY FL and an excess of AZD2281 (Figure   26 
5B) than in cells treated with AZD2281-BODIPY FL alone (Figure 5A). Moreover, addition of 
AZD2281 displaced AZD2281-BODIPY FL from the nucleus of cells (where PARP1/2 are 
localized). Together, these data indicate selective uptake of AZD2281-BODIPY FL at PARP1/2. 
All images are adjusted with the same leveling parameters to ensure comparability of 
fluorescence intensities.  
3.1.4 CoXlocalization!of!AZD2281XBODIPY!FL!with!PARP1/2!
To characterize and quantify the degree of AZD2281-BODIPY FL co-localization with PARP1/2 
in cells, I performed immunocytochemistry with simultaneous AZD2281-BODIPY FL 
incubation as described in section 2.4.2 (Figure 6, Figure 7). Representative images of anti-
PARP1/2 and AZD2281-BODIPY FL staining are provided in Figure 6. In all cell lines, anti-
PARP1/2 and AZD2281-BODIPY FL both localized to the nucleus as defined by Hoechst 33342 
staining. Fluorescence measurements were normalized to control wells to account for baseline 
autofluorescence of cells (515 nm; AZD2281-BODIPY FL) or for non-specific secondary 
antibody binding (670 nm; anti-PARP1/2). Co-localization of anti-PARP1/2 and AZD2281-
BODIPY FL fluorescence signals was quantified as a Pearson’s correlation coefficient 
comparing intensity of each pixel in the red and green channels, respectively (Rcoloc = 0.95). This 
correlation was similar for other cancer cell lines tested (ovarian and pancreatic cancer cell 
lines). A summary of fluorescent signal intensities for anti-PARP1/2 (670 nm) and AZD2281-
BODIPY FL (515 nm) across all cell lines investigated is provided in Figure 7. Three biological 
replicates and four technical replicates per biological replicate (for a total of twelve wells per cell 
line) were analyzed by measuring the weighted average of fluorescence intensity over at least 
twenty cells per well in ImageJ. Anti-PARP1/2 signal correlated with AZD2281-BODIPY FL 
signal across all cell lines (R
2 = 0.858; Figure 7B), indicating that PARP1/2 expression levels are 
associated with AZD2281-BODIPY FL signal strength in vitro.   27 
3.2 In1vivo!behavior!of!AZD2281Xderived!imaging!agents!
3.2.1 Identification!of!cell!types!that!accumulate!AZD2281XBODIPY!FL!
To determine if AZD2281-BODIPY FL accumulates in cancerous cells or normal cells (e.g. 
macrophages) in vivo, Rainer Kohler and I measured probe uptake in HT1080 cells implanted 
into dorsal skin chambers of Nu/Nu mice as described in section 2.5.2. Co-localization (yellow) 
of AZD2281-BODIPY FL (green) and tumor expressed H2b-apple chromatin (red) was observed 
(Figure 8). Localization of AZD2281-BODIPY FL to macrophages (blue) does occur as well, but 
to a lower extent. This finding recapitulated the low uptake of AZD2281-BODIPY FL by 
leukocytes observed in vitro by immunocytochemistry (Figure 7) in the mouse leukemic 
monocyte macrophage cell line RAW 264.7. Therefore, AZD2281-BODIPY FL acts as a 
targeted probe for PARP1/2 in vivo and does not target tumors based on their increased 
macrophage population, which may occur for other molecular markers like Annexin Vivo 
(unpublished data from Sarah Earley). 
3.2.2 Quantification!of!AZD2281XBODIPY!FL!uptake!in!xenografts!
To quantify AZD2281-BODIPY FL uptake in tumor xenografts, Nu/Nu mice with four different 
tumors in their flanks and shoulders were injected with probe, sacrificed, and their tumors 
excised for imaging and Western blot as described in section 2.5.3. I prepared tumor xenografts 
and AZD2281-BODIPY FL injections and performed Western blots, while Thomas Reiner 
excised the tumors and other tissue samples from sacrificed mice. Because the skin of Nu/Nu 
mice fluoresces green and overlaps with the emission spectrum of AZD2281-BODIPY FL (peak 
515 nm), tumors and control muscle tissue samples were removed from the mice for immediate 
standalone imaging (Figure 9). Tumor fluorescence intensity per unit surface area at 515 nm was 
higher than that of muscle tissue (Figure 9B). Furthermore, differences in fluorescence intensities   28 
at 515nm between different tumor types reflected differences in PARP1/2 expression quantified 
in vitro by immunocytochemistry (Figure 7). A2780 cells, which had the highest level of 
PARP1/2 expression, had the highest relative fluorescence intensity of the four xenografted cell 
lines. Decreasing levels of fluorescence at 515 nm for PANC1, SKOV3, and MIA PaCa2 were 
observed in that order, corresponding to decreasing levels of PARP1/2 measured by in vitro 
immunocytochemistry.  
3.2.3 Pharmacokinetics!of!18FXAZD2281!
Pharmacokinetic data for AZD2281-BODIPY FL and 
18F-AZD2281 were measured by Thomas 
Reiner and Ned Keliher as described in section 2.5.5. Blood half-life of AZD2281-BODIPY FL 
was measured to be 6.3 minutes (R
2 = 0.974; Figure 10). Blood half-life of 
18F-AZD2281 was 
measured to be 12.4 minutes (R
2 = 0.828; Figure 11A). Biodistribution of 
18F-AZD2281 was 
evaluated at 2 hours and 18 hours post-injection by gamma counter analysis on tissue samples; 
18F-AZD228 undergoes hepatobiliary excretion (3.9 ± 0.9 and 3.1 ± 1.6 %ID/g for liver and 
small intestines, respectively, Figure 11B) and accumulates in the feces (4.3 ± 2.3 %ID/g, Figure 
11C). 
3.2.4 Quantification!of!18FXAZD2281!uptake!in!xenografts!
To quantify 
18F-AZD2281 uptake in tumor xenografts, Nu/Nu mice with four different tumors in 
their flanks and shoulders were injected with probe, imaged with PET-CT, sacrificed, and their 
tumors excised for Western blot analysis as described in sections 2.5.4 and 2.5.6 (Figure 12). I 
prepared tumor xenografts, processed excised tumors and performed Western blots, while 
Thomas Reiner and Ned Keliher prepared 
18F-AZD2281 injections and Jessica Truelove assisted 
with PET-CT imaging. Standardized uptake values for 
18F-AZD2281 correlated with PARP1/2 
expression quantified from excised tumor Western blot band densities measured with ImageJ   29 
(R
2=0.933; Figure 12A). PET-CT images of tumors show highest levels of probe accumulation 
in the center of the tumor (representative images of A2780 tumor provided in Figure 12B). 
3.2.5 Selective!uptake!of!18FXAZD2281!at!PARP1/2!
Uptake of 
18F-AZD2281 and 
18F-FDG by tumors was compared over a series of PET-CT 
experiments in Nu/Nu mice bearing A2780 tumors in their flanks as described in sections 2.5.4 
and 2.5.6. Baseline PET-CT images and SUVs were obtained for both 
18F-FDG and 
18F-
AZD2281 on day 0 (Figure 13). Because both probes were administered to the same mice on the 
same day, 
18F signal from the first probe would not have completely decayed prior to 
administration of the second probe. Thus, images and SUVs for 
18F-AZD2281 were generated 
first, and signal for 
18F-FDG was calculated by subtracting the previously measured and decay-
corrected 
18F-AZD2281 signal from the composite 
18F-AZD2281 plus 
18F-FDG signal. 
Administration of cold AZD2281 led to a significant decrease in SUVs for images generated 
with 
18F-AZD2281 but not for images of the same tumors generated with 
18F-FDG (P<0.001), 
indicating selective uptake of 
18F-AZD2281 at the targets of AZD2281 (i.e. PARP1/2) (Figure 
13). Moreover, these data indicate that PARP1/2 inhibition can be quantified in vivo with 
18F-
AZD2281. 
  !  30 
Chapter!4: Discussion!
Our results indicate that AZD2281-derived imaging probes can accurately quantify PARP1/2 
expression and inhibition in vitro and in vivo. Although it was previously shown that 
18F-
AZD2281 could image xenografts of a BRCA-mutant cell line (MDA MB436),
44 here we 
showed that 
18F-AZD2281 has expanded utility against other tumors with a range of PARP 
expression and that SUVs correlate with level of PARP expression. AZD2281-BODIPY FL was 
observed to co-localize with PARP1/2 in nuclei and nucleoli in vitro and accumulated in tumor 
cells in vivo. 
18F-AZD2281 also localized to tumor xenografts in vivo.  
 
Of particular interest, PARP1/2 inhibition with AZD2281 had little effect on 
18F-FDG imaging, 
whereas 
18F-AZD2281 imaging produced significantly reduced signal as expected when the drug 
competes the probe off its target. These results suggest that while 
18F-FDG signal changes are 
unlikely to be useful in measuring PARP inhibitor uptake, 
18F-AZD2281 could be valuable in 
ongoing and future clinical trials of PARP inhibitors for direct, noninvasive quantification of 
drug uptake by tumors. The ability to image drug uptake could prove valuable in understanding 
situations where PARP inhibitor dose response differences are not significant
52 or in identifying 
tumors that have become resistant to PARP inhibition. 
18F-AZD2281 might also be useful in the 
prospective identification of patients with PARP-overexpressing cancers, who may benefit from 
treatment with PARP inhibitors. Direct quantification of PARP1/2 in patient tumors with 
18F-
AZD2281 could help address the growing demand for tests to rapidly identify “BRCAness,” a 
term referring to defective homologous recombination, that leads to susceptibility to PARP 
inhibition.
53 
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Two different AZD2281-derived probes were investigated for their separate abilities to measure 
PARP1/2, and we found that signal from AZD2281-BODIPY FL correlated well with signal 
from 
18F-AZD2281 in vivo (R
2
means= 0.96; Figure 14). These data are compatible with the probes’ 
shared imaging mechanism through targeted, selective uptake at PARP1/2 enzymes. Importantly, 
these data demonstrate that the chosen side chain modification did not greatly alter binding 
kinetics. 
4.1 Advantages!and!limitations!of!in1vitro1measures!of!PARP1/2!expression!
PARP1/2 expression across the panel of cell lines was evaluated by both Western blotting 
(Figure 4) and immunocytochemistry (Figure 7). Although Western blotting is only semi-
quantitative, the most obvious limitation of Western blotting in this project was the use of 
multiple gels for the large number of cell lines screened. Relative amounts of PARP protein 
cannot be compared across gels, only within a single gel. Moreover, the metabolic enzyme 
GAPDH that was used as a loading control could be expressed at different levels in different 
cancers, though GAPDH is expressed highly at all times in most cells. For example, ten percent 
of total soluble skeletal muscle protein is GAPDH.
54 Choice of loading control in cancer studies 
is particularly challenging. Despite variations that are known to exist between cancer types in 
GAPDH expression,
54 the abundance of this enzyme compared to proteins of interest (i.e. PARP) 
still permits a rough, semi-quantitative approach to blot interpretation. 
 
Keeping these limitations of Western blotting in mind, differences between the results obtained 
with blotting versus immunocytochemistry were apparent. For example, cell line A2780 appears 
to have moderate PARP1/2 expression by Western blot compared to the other cell lines 
evaluated, while A2780 had the highest PARP1/2 expression (as well as the highest level of 
AZD2281-BODIPY FL uptake) by immunocytochemistry. Cells used for Western blotting   32 
versus immunocytochemistry were unavoidably subjected to slightly different stresses; for 
example, some of the discrepancy may be attributable to differences in cell line growth 
conditions, including medium pH and confluency. For Western blots, slight variances in gel 
composition or experimental parameters (e.g. reagents, film exposure times) could be 
additionally responsible for some of the divergence. Because immunocytochemistry for all cell 
lines was performed on 96-well plates with multiple biological and technical replicates over 
three independent experiments, the data obtained from the immunocytochemistry experiment is 
stronger and was thus used for quantification of in vitro PARP1/2 expression. 
 
The limitations of applying data gained from in vitro experiments to in vivo models were also 
apparent; while lysates collected from cells grown in vitro displayed higher PARP1 than PARP2 
expression by Western blot (Figure 4), cell line-derived xenografts excised from mice 
demonstrated higher PARP2 than PARP1 expression (Figure 9, Supplementary Figure 1). These 
differences are unlikely to have arisen by random error since trends of relative PARP1 and 
PARP2 expression were consistent across in vitro and in vivo samples. It is possible that the 
exposure to different sets of stresses (e.g. cell culture flasks/medium vs. subcutaneous 
vascularized microenvironment) led to systematic differences in gene expression. Nevertheless, 
because AZD2281 and its derived imaging agents bind both PARP1 and PARP2 with nanomolar 
affinity (Figure 2, Figure 3), and because both enzyme targets are expressed under in vitro and in 
vivo conditions, AZD2281-BODIPY FL and 
18F-AZD2281 accumulated both in cells and in 
xenografts.  
 
Cell lines are laboratory tools that do not recapitulate all features of naturally arising tumors in 
patients. However, clinical trial data for AZD2281 suggest that PARP1/2 dependence is not   33 
unique to certain tumor types but is a feature shared by a significant portion of human cancers, 
irrespective of BRCA status.
53 For example, in one study of 65 patients with ovarian carcinoma, 
41% of patients with BRCA mutations and 24% of patients without BRCA mutations 
experienced objective responses to treatment with AZD2281.
55 Other research has confirmed that 
defects in tumor suppressor pathways besides BRCA (such as loss of PTEN) lead to sensitization 
to PARP inhibitors via synthetic lethality, suggesting upregulation of PARP in these tumors.
39 
Because PARP overexpression does occur in human cancers, AZD2281-derived imaging agents 
can perhaps be translated to certain cohorts of patients. 
4.2 Advantages!and!limitations!of!in1vivo!models!of!PARP1/2!imaging!
Xenografts are useful tools because they are easy to set up without sacrifice of the key qualities 
of an in vivo microenvironment (e.g. vascularization, macrophage involvement). Yet, the 
pancreatic and ovarian cell lines evaluated in my project were after all in inappropriate anatomic 
locations relative to where these cancers would normally arise. Orthotopic models of these 
cancers are an important future step in the evaluation of AZD2281-derived imaging agents and 
will be especially helpful in evaluating potential signal interference from areas of high AZD2281 
uptake like liver or intestines. Just as abdominal imaging with 
18F-FDG necessitates low blood 
glucose levels and can sometimes require administration of furosemide or catheterization, steps 
to reduce nonspecific uptake of AZD2281-derived imaging agents (such as administration of 
low-dose AZD2281 before imaging) may also prove necessary under certain circumstances. In 
contrast with conventional chemotherapy, therapeutic doses of AZD2281 produce few adverse 
effects
41 and a priming dose prior to imaging may be reasonable.   34 
4.3 Future!directions!
In patients taking certain chemotherapeutic agents, drug-mediated DNA damage in normal tissue 
could upregulate PARP and increase background signal on 
18F-AZD2281 imaging. While we 
expect that this background noise would be minimal (normal cells should apoptose in the context 
of severe DNA damage), the effects of cytotoxic drugs on normal tissue may end up being a 
limiting factor for use of 
8F-AZD2281 in patients undergoing therapy with DNA-damaging drugs 
like cisplatin. Future experiments to evaluate 
18F-AZD2281 signal in mice treated with cytotoxic 
agents should be undertaken. 
 
In addition to further testing of AZD2281-derived imaging agents in orthotopic and 
chemotherapy-treated models of cancer, experiments to evaluate uptake of 
18F-AZD2281 by 
inflamed tissue or benign lesions would be useful for determining the potential utility of the 
imaging agent over 
18F-FDG, which can be of limited utility in such situations. Also, future 
experiments with tumors of varying sizes could be undertaken to explore the potential for 
18F-
AZD2281 imaging in smaller numbers of cells, as our in vivo xenograft model of cancer had 
relatively large, palpable tumors.  
 
Over the course of our in vivo PET-CT experiments, we noticed that 
18F-FDG accumulated 
predominantly in the metabolically active peripheral regions of the growing tumors while 
18F-
AZD2281 appeared to accumulate in the central regions (Figure 12,Figure 13). The differences 
in tropism of the probes may be due to tumor heterogeneity; while 
18F-FDG is known to avoid 
fibrotic or necrotic tissues, 
18F-AZD2281 may accumulate best in areas of stress (such as a 
hypoxic or necrotic tumor core). Histological examination of xenograft biopsies after 
18F-FDG   35 
and 
18F-AZD2281
 PET-CT imaging should be undertaken to identify any differences in cell 
status in areas of differential probe uptake. 
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Chapter!5: Conclusions!
Together, these data indicate that AZD2281-based imaging agents are useful tools for in vitro 
and in vivo targeted visualization of PARP1/2 as well as its inhibition with emerging PARP 
inhibitors. As the pool of PARP inhibitors in clinical trials (summarized elsewhere)
40,56 continues 
to grow, non-invasive tools for quantification of PARP inhibition may become increasingly 
useful. Although we only imaged AZD2281-mediated inhibition of PARP in this project, PET-
CT with 
18F-AZD2281 may indeed be able to quantify inhibition by any competitive PARP 
inhibitor that binds to the catalytically active site. 
 
More broadly, this project has demonstrated the feasibility and potential applicability of using 
modified, targeted small molecules as imaging probes. Radiofluorination of other drugs could 
facilitate deeper understanding of the complicated workings of a variety of cancers as well as a 
number of diseases in addition to cancer. Such companion imaging agents could be readily 
designed and synthesized by the rapid, generic process laid out by the Weissleder group.
44,43 
Patient-specific data will become increasingly vital in the management of cancers, and targeted 
PET-CT has the potential for meeting this need. 
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Summary!
This project investigated the targeted molecular imaging of pancreatic and ovarian cancers with 
novel inhibitor-derived probes. Specifically, fluorescent and radioactive derivatives of 
AZD2281, a competitive PARP1/2 inhibitor currently in clinical trials for a variety of cancers, 
were screened in a panel of pancreatic and ovarian cancer cell lines determined to overexpress 
PARP1/2. We hypothesized that PARP1/2 expression and inhibition could be quantified 
accurately with AZD2281-derived probes. 
 
To test this hypothesis, a panel of pancreatic ductal adenocarcinoma and ovarian carcinoma cell 
lines were characterized by Western blot and immunocytochemistry for PARP1/2 expression. 
AZD2281-derived probes were observed to co-localize with PARP1/2 in the nucleus and 
especially in the nucleoli of all cell lines examined in vitro. Accumulation of AZD2281-
BODIPY FL correlated with PARP1/2 expression, with the highest PARP1/2 expressers accruing 
the most AZD2281-BODIPY FL, indicating that PARP1/2 expression is a determinant of 
fluorescent signal strength of AZD2281-BODIPY FL in vitro. 
 
To determine the utility of AZD2281-derived probes in vivo, four cell lines representing a range 
of PARP1/2 expression levels were xenografted into Nu/Nu mice. Mice bearing four tumor types 
each were imaged with AZD2281-BODIPY FL or 
18F-AZD2281, sacrificed, and their tumors 
excised for stand-alone imaging and Western blot. Tumor fluorescence and SUVs from PET-CT 
correlated with tumor PARP1/2 expression determined by Western blot, indicating that PARP1/2 
expression level is a determinant of fluorescent and radioactive signal strength in vivo. 
Significantly more AZD2281-derived probe accumulated in tumors than in control muscle tissue,   38 
indicating that both probes are useful for detecting PARP1/2-overexpressing cells amongst 
background normal tissue in vivo.  
 
We also compared our radioactive derivative 
18F-AZD2281 with the current standard radiotracer 
of PET imaging, 
18F-FDG. A2780 cells, which were determined to highly express PARP1/2, 
were implanted into the flanks of a cohort of mice and allowed to grow. These mice were imaged 
before and after receiving doses of unmodified AZD2281 drug in triplicate. While SUVs for 
18F-
FDG were unchanged by the administration of AZD2281, 
18F-AZD2281 SUVs significantly 
decreased compared to baseline signal, in keeping with the ability of similarly structured 
molecules to compete at their target enzyme. These data indicate that 
18F-AZD2281 may find use 
in quantifying PARP1/2 inhibition noninvasively.  
 
Because it binds to the active site of PARP1/2, 
18F-AZD2281 could be used to noninvasively 
quantify inhibition by other competitive PARP inhibitors, though we only investigated AZD2281 
inhibition in this project. We also believe 
18F-AZD2281 could be useful for prospective 
identification of patients with cancers that may be susceptible to treatment with PARP inhibitors.  
 
More generally, the modification of targeted small molecules may enable noninvasive studies of 
other enzyme targets in patients with a variety of diseases. Using targeted radiotracers in PET-
CT imaging has the potential to meet the growing demand for rapid methods of ascertaining 
patient-specific cancer properties, such as susceptibility to treatment, early identification of 
resistance, and recurrence.  
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Tables!
Table 1. Factors Leading to Increased or Decreased 
18F-FDG Uptake in Tumors 
  Increased 18F-
FDG uptake  
Decreased 18F-
FDG uptake 
Viable cancer cell number  ✕   
Tumor perfusion  ✕   
Hypoxia  ✕   
Glucose transporter expression  ✕   
Hexokinase activity  ✕   
Inflammation or infection  ✕   
Receptor antagonists  ✕   
Chemotherapy (acute)  ✕   
Radiation therapy (acute)  ✕   
Receptor blockade    ✕ 
Chemotherapy (effective)    ✕ 
Radiation therapy (chronic)    ✕ 
Hyperglycemia    ✕ 
Insulin    ✕ 
Necrosis    ✕ 
Modified from Vallabhajosula et al.
18 
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Figures!
 
   
Figure 1. Chemical structures of A) AZD2281 (Olaparib; Selleck Chemicals, Houston, TX), B) AZD2281-BODIPY 
FL, and C) 
18F-AZD2281. (Reiner and Lacy et al 2012)
45 
 
 
Figure 2. IC50 of AZD2281-BODIPY FL measured for A) PARP1 with the Universal PARP1 Colorimetric Assay 
Kit (Trevigen; 4677-096-K) and for B) PARP2 with the PARP2 Chemiluminescent Assay Kit (BPS Biosciences; 
80552).  
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Figure 3. IC50 curves for AZD2281-BODIPY FL (blue) and 
19F-AZD2281 (red) measured for PARP1 with the 
Universal PARP1 Colorimetric Assay Kit (Trevigen; 4677-096-K). (Reiner and Lacy et al 2012)
45 
 
 
 
Figure 4. PARP1 expression in cell lines derived from human ovarian papillary serous adenocarcinomas (UCI101, 
UCI107, A2780, OVCAR3, CaOV3, SKOV3, OV-90), ovarian serous cystoadenocarcinoma (OVCAR429), 
pancreatic ductal adenocarcinomas (Panc1, Paca2), and mammary adenocarcinoma (MDA MB231, MDA MB436). 
Benign ovarian cyst Hs832 (noncancerous control), mouse leukemic monocyte macrophage RAW 264.7, and human 
embryonic kidney cell line 293T (positive control) are also included for comparison. Anti-PARP1/2 Rab (Santa 
Cruz Biotechnology; SC-7150), anti-GAPDH Gab (R&D Systems; AF5718). 
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Figure 5. Cells were seeded on 8-well chamber slides and allowed to attach overnight. AZD2281-BODIPY FL (1 
μM) (A) or AZD2281-BODIPY FL (1 μM) + AZD2281 (100 μM) (B) was added to live cells and incubated for 20 
minutes. Cells were then fixed, stained with anti-PARP antibody (Millipore; MAB3290), mounted, and imaged with 
Nikon 80i (60x, 1x zoom). A) MDA MB231, B) MDA MB231 blocked with cold AZD2281. Images are 
representative of AZD2281-BODIPY FL behavior observed in all cell lines investigated with blocking expeirments. 
 
 
 
Figure 6. PANC1 cells were seeded on 96-well plates and allowed to attach overnight. AZD2281-BODIPY FL (1 
μM) was added to live cells and incubated for 20 minutes. Cells were then fixed, stained with anti-PARP1/2 
antibody (Santa Cruz Biotechnology; SC-7150), mounted, and imaged with the Deltavision microscopy system on 
the Olympus IX71. Co-localization was assessed with ImageJ. (Reiner and Lacy et al 2012)
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Figure 7. Cells were seeded at a density of 5,000 cells per well in 96-well plates and were grown for 48 hours. 
AZD2281-BODIPY FL (1 μM) was added to live cells and incubated for 20 minutes. Cells were then fixed, stained 
with anti-PARP1/2 antibody (Santa Cruz Biotechnology; SC-7150), mounted, and imaged with the 
Deltavision/Olympus IX71 microscopy system. Fluorescence intensities were measured with ImageJ. A. 
Fluorescence intensities for AZD2281-BODIPY FL and anti-PARP1/2 are plotted for each cell line. B. Mean 
AZD2281-BODIPY fluorescence intensity plotted against mean anti-PARP1/2 fluorescence intensity, with 95% 
confidence band shown by dotted blue curves. Twelve replicate wells with at least 20 cellular fluorescence 
measurements per well were used for each cell line. (Reiner and Lacy et al 2012)
45 
 
 
Figure 8. HT180 cells stably expressing H2b-apple, which labels chromatin, were implanted into dorsal skin 
chambers of Nu/Nu mice and allowed to vascularize over 8 days. Mice were then injected with 75 nmoles of 
AZD2281-BODIPY FL and imaged with the Olympus FV1000MPE. A composite image (D) shows co-localization 
(yellow) of tumor expressed H2b-apple chromatin (A; red) and AZD2281-BODIPY FL (B; green). AZD2281-
BODIPY FL does not co-localize with CLIO-VivoTag680, which labels leukocytes (C; blue). 
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Figure 9.!Nu/Nu!mice!bearing!A2780,!PANC1,!MIA!PaCa2!and!SKOV3!tumors!in!their!flanks!and!shoulders!
were!injected!with!either!AZD22815BODIPY!FL!(75!nmoles!in!7.5!µL!DMSO,!67.5!µL!PEG400,!150!µL!1X!PBS)!
or!vehicle!and!sacrificed!45!minutes!post5injection.!Tumors!and!muscle!tissue!from!both!experimental!and!
control!cohorts!were!excised!and!their!fluorescence!was!measured!on!the!Olympus!OV110.!A).!Arrangement!
of!tumor!sites!to!be!xenografted!onto!an!isoflurane!anesthetized!Nu/Nu!mouse.!B).!Visible!light!and!
fluorescence!images!of!the!excised!tissues!from!both!AZD22815BODIPY!FL5injected!and!vehicle5injected!mice.!
Western!blot!of!excised!tumor!lysate!showing!PARP1!and!PARP2!expression!is!also!shown.!C).!Relative!
fluorescence!intensities!of!the!excised!tissues!normalized!to!vehicle5only!fluorescence!level.!
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Figure 10. One Nu/Nu mouse bearing A2780, PANC1, MIA PaCa2, and SKOV3 tumors in its shoulders and flanks 
was imaged on the Olympus FV1000MPE over the course of 60 minutes to calculate AZD2281-BODIPY FL blood 
half-life. A). Vascular fluorescence over time, normalized to vascular fluorescence before AZD2281-BODIPY FL 
injection. B). Extravascular fluorescence over time, normalized to extravascular fluorescence before AZD2281-
BODIPY FL injection. C). Representative images at indicated time points pre- and post- probe injection of a 
particular blood vessel in the field of the DSC. AZD2281-BODIPY FL is represented in green, HT1080 H2b-apple 
expressing cells are in blue, and macrophages are in red. 
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Figure 11. Blood half-life and biodistribution of 
18F-AZD2281. A). Blood half-life was determined with three 
C57BL/6 mice administered with 100 ± 25 µCi  
18F-AZD2281 by tail vein intravenous injection formulated in 70% 
1X PBS, 10% DMSO in water, 20% DMAC:Solutol (1:1). Blood sampling was performed by retro-orbital bleed 
using tared capillary tubes. Samples were weighed, and activity was measured by γ counter. B) & C). Six C57BL/6 
mice were injected with 100 ± 25 µCi or 600 ± 50 µCi 
18F-AZD2281 by tail vein iv injection. Animals were 
sacrificed at B) 2 h (n = 3) or C) 18 h (n = 3) after injection. Tissues were excised and weighed, and activity was 
measured by γ counter. (Reiner and Lacy et al 2012)
45 
 
 
Figure 12. In vivo imaging of PARP. Nu/Nu mice bearing A2780, Panc1, MIA PaCa2 and SKOV3 tumors (n = 3) 
in their flanks and shoulders were injected with 500 ± 50 µCi 
18F-AZD2281. Ninety minutes post-injection, the mice 
were subjected to PET imaging. A). Standardized uptake values (SUVs) determined by PET imaging correlated with 
PARP1/2 expression determined by Western blot of excised tumor lysate. B). Representative coronal (top) and axial 
(bottom) CT, PET, and PET/CT slices for an A2780 tumor.!(Reiner and Lacy et al 2012)
45!
0
1
2
3
4
5
Liver
Int. (S)
Feces
Kidney
Spleen
Stomach
Int. (L)
Muscle
Skin
Pancreas
Heart
Lung
Fat
Fat
Int. (S)
Kidney
Liver
Int. (L)
Spleen
Stomach
Muscle
Pancreas
Skin
Heart
Lung
Feces
0
1
2
3
4
5
Liver
Int. (S)
Feces
Kidney
Spleen
Stomach
Int. (L)
Muscle
Skin
Pancreas
Heart
Lung
Fat
Fat
Int. (S)
Kidney
Liver
Int. (L)
Spleen
Stomach
Muscle
Pancreas
Skin
Heart
Lung
Feces
2
4
6
8
10
12
0 10 20 30 40 50 60
time [min]
B)
18F-AZD2281, 2h
18F-AZD2281, 18h
%
I
D
/
g
t1/2 (weighted) = 12.4 min 
R2 =0.828
18F-AZD2281
%
I
D
/
g
A)
%
I
D
/
g
0
1
2
3
4
5
%
I
D
/
g
0
1
2
3
4
5 C)  50 
 
Figure 13. Nu/Nu mice bearing A2780 tumors (n = 3) in their flanks were injected with 440 ± 40 µCi 
18F-AZD2281 
and PET imaged 2 hours later. Thereafter, the same mice were intravenously injected with 523 ± 47 µCi 
18F-FDG 
and subjected to a second round of PET imaging. After 
18F-FDG imaging, the mice were injected with 1 mg 
AZD2281 intraperitoneally. The next day, mice were treated with 0.5 mg AZD2281 intravenously. Mice were then 
imaged as they had been on the first day. Three replicates of this treatment/imaging protocol were performed on the 
same mice over three days. A total of ten complete serial sessions were acquired for each mouse. Tumor SUV 
margins were drawn to span the entire tumor using the Siemens Research Workplace v3.0 analysis application. SUV 
data from 
18F-AZD2281 PET images were decay corrected to the start of 
18F-FDG PET imaging and used to correct 
18F-FDG SUV data. (Reiner and Lacy et al 2012)
45!
 
   
Figure 14. In vivo comparison of signals measured in tumor xenografts from 
18F-AZD2281 (SUVs) and AZD2281-
BODIPY FL (surface reflectance; arbitrary units). Nu/Nu mice bearing A2780, Panc1, MIA PaCa2 and SKOV3 
tumors in their flanks and shoulders were used for PET-CT and fluorescence imaging. (Reiner and Lacy et al 2012)
45 
  !
SUVs correlated to Mab Immunofluorescence
0 50 100 150
0.2
0.3
0.4
0.5
PARP1/PARP2 Immunofluorescence [%]
(determined by in vitro experiments)
1
8
F
 
A
Z
D
2
2
8
1
 
S
U
V
s
 
(
d
e
t
e
r
m
i
n
e
d
 
b
y
 
P
E
T
)
SUVs correlated to TR345
0 5000 10000 15000 20000 25000
0.0
0.1
0.2
0.3
0.4
0.5
1
8
F
 
A
Z
D
2
2
8
1
 
S
U
V
s
 
(
d
e
t
e
r
m
i
n
e
d
 
b
y
 
P
E
T
)
AZD2281-BODIPY FL uptake
(determined by surface reflectance)
90% conﬁdence band
R2 = 0.95 (mean)
R2 = 0.62 (each replicate)
95% conﬁdence band
R2 = 0.96 (mean)
R2 = 0.80 (each replicate)
muscle
MIA PaCa2
SKOV3
Panc1
A2780
MIA PaCa2
SKOV3
Panc1
A2780  51 
Supplementary!Figures!
   
 
Supplementary Figure 1. PARP1 and PARP2 expression evaluated by Western blot for excised tumors from three 
Nu/Nu mice bearing four tumors (A2780, Panc1, SKOV3, MIA PaCa2) each in their flanks and shoulders. Anti-
PARP1/2 Rab (Santa Cruz Biotechnology; SC-7150), anti-GAPDH Gab (R&D Systems; AF5718). 
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